# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
UK regulators reprimand Novo Nordisk for failing to disclose nearly $10 million in fees and expenses. The PMCPA cites breaches ...
Carisma notified Novartis Pharmaceuticals of its termination of the Manufacturing and Supply Agreement, dated March 1, 2023, re...
Jefferies analyst Peter Welford maintains Novartis (NYSE:NVS) with a Buy and raises the price target from $121 to $122.5.
A Mississippi judge upheld a state law requiring drugmakers to offer discounts on medications through third-party pharmacies fo...
Nestle's new Vital Pursuit brand targets individuals on weight-loss drugs without mentioning medications on packaging, addr...
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover.
Trevena shares dropped 33.7% to $0.23 with a session volume of 23.65 million. Notably, TRV045 did not cause S1P1R desensitizati...
-Reuters
Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market l...